Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T4JQ
|
|||
| Former ID |
DNC003126
|
|||
| Drug Name |
Butanoic Acid
|
|||
| Synonyms |
butyric acid; butanoic acid; n-Butyric acid; 107-92-6; n-Butanoic acid; propylformic acid; ethylacetic acid; 1-propanecarboxylic acid; Butanic acid; butyrate; 1-Butyric acid; Buttersaeure; butanoate; Kyselina maselna; Butyric acid (natural); Propanecarboxylic acid; Buttersaeure [German]; 1-butanoic acid; FEMA Number 2221; Kyselina maselna [Czech]; FEMA No. 2221; CCRIS 6552; HSDB 940; butoic acid; Ethyacetic Acid; 2-butanoate; NSC 8415; UNII-40UIR9Q29H; UN2820; AI3-15306; EINECS 203-532-3; BRN 0906770; CH3-[CH2]2-COOH; 40UIR9Q29H
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C4H8O2
|
|||
| Canonical SMILES |
CCCC(=O)O
|
|||
| InChI |
1S/C4H8O2/c1-2-3-4(5)6/h2-3H2,1H3,(H,5,6)
|
|||
| InChIKey |
FERIUCNNQQJTOY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 107-92-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3545, 74110, 584341, 587668, 639195, 829106, 841341, 3132316, 4802290, 7849658, 7886373, 8137924, 8145230, 8150539, 10318186, 10503556, 11120324, 11120812, 11121300, 11405819, 11447352, 11528267, 15363437, 24424045, 24438641, 24851531, 24891550, 24900934, 24900935, 26711808, 26715116, 26746547, 30339108, 30388555, 31062314, 32452557, 37374541, 37388172, 37904320, 46393305, 46505927, 48414707, 48417171, 48423012, 53787580, 56464546, 57320085, 76464313, 81062787, 81064461
|
|||
| ChEBI ID |
CHEBI:30772
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Butyricicoccus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Butyricicoccus was increased by Butyric acid. | |||
|
Studied Microbe: Eubacterium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | IL10 -/- mice | Experimental Sample | Faeces | |
| Disease or Condition | Inflammatory bowel disease | |||
| Description | The abundance of Eubacterium was increased by Butyric acid (p = 0.003). | |||
|
Studied Microbe: Lachnospiraceae bacterium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Ulcerative colitis | |||
| Description | The abundance of Lachnospiraceae bacterium was increased by Butyric acid. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Bacteroidetes
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | IL10 -/- mice | Experimental Sample | Faeces | |
| Disease or Condition | Inflammatory bowel disease | |||
| Description | The abundance of Bacteroidetes was decreased by Butyric acid (p = 0.046). | |||
|
Studied Microbe: Firmicutes
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | IL10 -/- mice | Experimental Sample | Faeces | |
| Disease or Condition | Inflammatory bowel disease | |||
| Description | The abundance of Firmicutes was increased by Butyric acid (p = 0.012). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cholinesterase (BCHE) | Target Info | Inhibitor | [4] |
| Panther Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||
| Muscarinic acetylcholine receptor 2 and 4 signaling pathway | ||||
| Nicotinic acetylcholine receptor signaling pathway | ||||
| WikiPathways | Irinotecan Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1059). | |||
| REF 2 | Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterol Motil. 2020 Oct;32(10):e13914. | |||
| REF 3 | Sodium Butyrate Reduces Colitogenic Immunoglobulin A-Coated Bacteria and Modifies the Composition of Microbiota in IL-10 Deficient Mice. Nutrients. 2016 Nov 24;8(12):728. | |||
| REF 4 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.